The CJC-1295/Ipamorelin Stack for Shoulder Surgery Recovery

If you've looked into peptides for shoulder surgery recovery beyond a surface level, you've almost certainly come across CJC-1295 and ipamorelin in the same sentence. They're typically prescribed together, administered as a single combined injection, and discussed as a unit rather than separately. There are good biological reasons for that pairing — and understanding why they're combined, what each does, and how timing relative to surgery matters will help you have a much more informed conversation with any physician you approach about this.

Two Different Mechanisms, One Common Goal

CJC-1295 and ipamorelin both stimulate growth hormone release, but they do it through entirely different receptors and pathways — and that's precisely why they work better together.

Ipamorelin is a GHRP — a growth hormone releasing peptide. It binds to the ghrelin receptor (GHSR) in the pituitary and hypothalamus, triggering a GH pulse. As I've discussed elsewhere, its defining feature is selectivity: it produces robust GH stimulation with minimal cortisol and prolactin elevation.

CJC-1295 is a GHRH analog — a synthetic version of the body's own growth hormone releasing hormone. It binds to the GHRH receptor, which is a separate receptor from the ghrelin pathway ipamorelin targets. CJC-1295 extends the duration and amplitude of the GH pulse by keeping the GHRH receptor activated.

Think of ipamorelin as the trigger and CJC-1295 as the amplifier. Ipamorelin initiates the GH pulse through the ghrelin pathway. CJC-1295 potentiates and extends that pulse through the GHRH pathway. The combined signal produces a GH release that is meaningfully larger than either compound produces alone — while remaining within the body's physiological feedback architecture.

DAC vs. No-DAC: Why the Formulation You're Prescribed Matters

CJC-1295 comes in two formulations: with DAC (Drug Affinity Complex) and without DAC. This distinction has significant clinical implications.

CJC-1295 with DAC binds to albumin in the bloodstream, dramatically extending its half-life to several days. This produces a prolonged elevation of baseline GH levels rather than a physiological pulse. Many physicians in this space prefer the no-DAC version — also called Modified GRF(1-29) or Mod GRF — because it produces a more pulse-like GH pattern that better mirrors the body's natural rhythm.

The no-DAC formulation has a short half-life (30–60 minutes), so it's administered in close proximity to ipamorelin and works synergistically during the active pulsatile window. Most perioperative protocols I'm aware of use the no-DAC formulation for this reason.

The Sleep-Pulse Physiology — Why Timing Matters Enormously

The largest natural GH pulse of the day occurs in the first few hours of deep sleep — typically 90 to 120 minutes after sleep onset. This is not a minor variation. Sleep-associated GH secretion can account for the majority of daily GH output in healthy adults.

Administering CJC-1295/ipamorelin 30–45 minutes before sleep aligns the exogenous peptide signal with this natural sleep-associated pulse. The combined effect can significantly amplify the GH and downstream IGF-1 output during the most biologically relevant window of the 24-hour cycle. Administering the stack at random times without attention to this physiology leaves the most important lever unpulled.

Why This Stack Matters Specifically for Shoulder Surgery Recovery

Shoulder surgery — whether rotator cuff repair or arthroplasty — creates several overlapping recovery demands:

• Tendon and soft tissue healing at the repair site
• Muscle recovery from pre-surgical atrophy (rotator cuff tears, particularly massive tears, cause significant muscle loss before surgery even occurs)
• Bone remodeling around anchors (cuff repair) or implant components (arthroplasty)
• Systemic anabolic support to counteract the catabolic stress response to surgery

IGF-1, the primary downstream mediator of CJC-1295/ipamorelin's effects, has documented roles in all four of these processes. The anabolic signaling cascade initiated by optimized GH pulsatility is not specific to one tissue type — it supports the entire biological environment of recovery.

For patients with documented low IGF-1 at baseline — which is more common than most surgeons screen for, particularly in older patients — the argument for optimizing GH axis signaling perioperatively is particularly compelling. A depleted anabolic environment is a hostile healing environment.

What to Ask a Prescribing Physician

If you're interested in whether this stack might be appropriate for your shoulder surgery recovery, these are the foundational questions worth asking:

• Will you check my baseline IGF-1 level before prescribing? (It should be checked — it's your primary monitoring marker)
• Are you using CJC-1295 with or without DAC, and why?
• What compounding pharmacy do you use, and can I see their certificate of analysis?
• How will you monitor my response, and what are the follow-up labs?
• What would prompt you to adjust or stop the protocol?

These questions accomplish two things: they help you understand the protocol, and they help you assess whether the physician prescribing it is operating with appropriate rigor. A physician who can't answer these questions clearly is not the right person to supervise your protocol.

⚠️  Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. BPC-157 and other peptides discussed here are not FDA-approved for these indications. Always consult your physician before starting any peptide protocol.

Related reading

• Ipamorelin: Why It's the Starting Point for Most of My Patients
• Why I Stop BPC-157 at Week 6 After Rotator Cuff Repair
• What Is BPC-157? A Shoulder Surgeon's Honest Take